MedTrace Logo

Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery

NCT07098780 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2025-08-01

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if tranexamic acid (TXA) helps reduce bleeding during bariatric surgery, such as laparoscopic sleeve gastrectomy (LSG) and mini gastric bypass (MGB). It will also look at how safe TXA is for people undergoing these procedures. The main questions it aims to answer are:

Does TXA reduce the amount of blood loss during bariatric surgery? Are there any side effects or complications in patients who receive TXA? Researchers will compare TXA to standard care (no TXA) to see if it is effective in reducing bleeding.

Participants will:

Receive either TXA or no TXA (placebo) before surgery Undergo standard bariatric surgery (LSG or MGB) Have their blood loss, hemoglobin levels, and any complications monitored during and after surgery

Conditions

Interventions

DRUG

Tranexamic Acid

At the time of incision, 1000mg of the drug would be given intravenous, followed by two postoperative doses of 1000mg eight hours apart.

OTHER

Normal Saline (Placebo)

At the time of incision, 10ml of the drug would be given intravenous, followed by two postoperative doses of 10ml eight hours apart.

Sponsors & Collaborators

  • Patel Hospital, Pakistan

    lead OTHER

Principal Investigators

  • Ghulam Murtaza, MBBS, FCPS, MRCS, MSc (epi) · Patel Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-12
Primary Completion
2025-07-31
Completion
2025-08-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07098780 on ClinicalTrials.gov